Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment

68Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

Eph receptor tyrosine kinases are critical for cell-cell communication during normal and oncogenic tissue patterning and tumor growth. Somatic mutation profiles of several cancer genomes suggest EphA3 as a tumor suppressor, but its oncogenic expression pattern and role in tumorigenesis remain largely undefined. Here, we report unexpected EphA3 overexpression within the microenvironment of a range of human cancers and mouse tumor xenografts where its activation inhibits tumor growth. EphA3 is found on mouse bone marrow-derived cells with mesenchymal and myeloid phenotypes, and activation of EphA3+/CD90+/Sca1+ mesenchymal/stromal cells with an EphA3 agonist leads to cell contraction, cell-cell segregation, and apoptosis. Treatment of mice with an agonistic α-EphA3 antibody inhibits tumor growth by severely disrupting the integrity and function of newly formed tumor stroma and microvasculature. Our data define EphA3 as a novel target for selective ablation of the tumor microenvironment and demonstrate the potential of EphA3 agonists for anticancer therapy. ©2014 AACR.

Cite

CITATION STYLE

APA

Vail, M. E., Murone, C., Tan, A., Hii, L., Abebe, D., Janes, P. W., … Lackmann, M. (2014). Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Research, 74(16), 4470–4481. https://doi.org/10.1158/0008-5472.CAN-14-0218

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free